Physician profile
Mark E Clarke
NPI 1790850584
$37,335.51
in general payments reported to CMS, 2019-2025
62 companies · $7,652 in 2025
The $7,652 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,676 · 2022: $6,551 · 2023: $8,090 · 2024: $7,367 · 2025: $7,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23,108.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,885.63 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,476.60 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $2,269.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $2,204.30 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $2,104.52 | 2022-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $1,903.40 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $1,887.46 | 2021-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $1,809.38 | 2021-2025 | Hetlioz, Fanapt |
| Sanofi-Aventis U.S. LLC | $1,496.91 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,425.41 | 2021-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Pfizer INC. | $1,409.61 | 2021-2025 | |
| Lilly USA, LLC | $1,389.50 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $1,334.55 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,196.93 | 2021-2023 | Trintellix |
| Antares Pharma, INC. | $822.86 | 2021-2025 | Xyosted, Tlando, Nocdurna |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $821.77 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $746.81 | 2021 | |
| Axsome Therapeutics, INC. | $692.36 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $445.34 | 2022-2025 | |
| Tolmar, INC. | $442.29 | 2023-2025 | Jatenzo |
| Corium, LLC | $438.57 | 2022-2024 | Azstarys |
| Phathom Pharmaceuticals, INC. | $426.61 | 2023-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $345.56 | 2023-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $344.97 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $338.08 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Otsuka America Pharmaceutical, INC. | $331.81 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $321.68 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $310.25 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $281.57 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $261.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $245.95 | 2022-2025 | Eliquis, Camzyos |
| Mylan Specialty L.P. | $235.48 | 2021-2024 | Yupelri, Yupelri |
| Idorsia Pharmaceuticals US INC | $205.02 | 2022-2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $189.18 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $161.30 | 2021-2024 | |
| Verona Pharma, INC. | $160.48 | 2025 | Ohtuvayre |
| Currax Pharmaceuticals LLC | $157.62 | 2021-2024 | Contrave |
| Nevro Corp. | $153.73 | 2021 | |
| Ardelyx, INC. | $143.44 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $140.16 | 2021 | |
| Abiomed | $133.03 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.76 | 2022 | |
| Eisai INC. | $116.43 | 2021 | |
| Cochlear Americas | $102.42 | 2024 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Acerus Pharmaceuticals Corporation | $102.09 | 2021-2022 | |
| Lucid Diagnostics INC. | $86.16 | 2024 | |
| Merck Sharp & Dohme LLC | $80.60 | 2023 | Verquvo, Belsomra, Steglatro |
| Bausch Health US, LLC | $74.15 | 2024-2025 | Wellbutrin, Aplenzin |
| Amarin Pharma, INC. | $73.06 | 2021-2022 | |
| Corcept Therapeutics | $70.97 | 2024 | Korlym |
| Verity Pharmaceuticals INC. | $64.73 | 2024-2025 | Tlando |
| Ibsa Pharma INC. | $56.50 | 2023 | Tirosint, Licart |
| Astellas Pharma US INC | $50.48 | 2025 | Veozah |
| Myriad Women'S Health, INC. | $43.60 | 2023 | Myrisk |
| Dexcom, INC. | $35.36 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $30.59 | 2022 | |
| Sumitomo Pharma America, INC. | $28.73 | 2024-2025 | Gemtesa |
| Almatica Pharma LLC | $28.43 | 2021-2022 | |
| Halozyme INC | $24.51 | 2023 | |
| Horizon Therapeutics Plc | $22.14 | 2021 | |
| Redhill Biopharma INC. | $19.34 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.26 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.